Advanced Proteome Therapeutics Moves Into Johnson & Johnson Innovation, JLABS @ Toronto


VANCOUVER, BC--(Marketwired - May 01, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8), a biotechnology company focused on producing technologies to perfect the use of antibody drug conjugates for the treatment of various cancers, is pleased to announce it has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto.

Advanced Proteome Therapeutics, currently operating in Boston, MA, will join other select early stage companies at the state of the art facility in Toronto starting May 1.

"Being selected by the Johnson & Johnson Innovation team to join JLABS @ Toronto and locating among a talented and diverse peer group is both an honour and extremely validating for our company," said Randal Chase, CEO of Advanced Proteome Therapeutics. "The work space and facilities allow us to continue advancing our research while being surrounded by fast growing and emerging companies."

JLABS @ Toronto is a 40,000 square-foot life science innovation center. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products -- either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

About APC

Advanced Proteome Therapeutics Corporation (APC) is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells, Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting the potential of this type of agent.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Contact Information:

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation
Dr. Randal D. Chase
President and Chief Executive Officer
Tel: 905-252-3629
http://www.advancedproteome.com

Advanced Proteome Therapeutics Corporation
Babak Pedram
Investor Relations
Virtus Advisory Group Inc.
Tel: 416-644-5081
bpedram@virtusadvisory.com